Why the study?
The study was designed to evaluate the relationship between temporal changes in renal function and long-term mortality in patients with HFrEF and to identify correlates of deteriorating renal function.
Do diabetes and male sex predict eGFR decline, and does eGFR decline increase mortality risk in patients with HFrEF?
Cohort (n=381)
Do diabetes and male sex predict eGFR decline, and does eGFR decline increase mortality risk in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
In patients with HFrEF, male sex and diabetes predict a 1-year decline in eGFR, which is associated with significantly higher long-term all-cause mortality.
Introduction: We aimed to evaluate the relationship between temporal changes in renal function and long-term mortality in patients with heart failure with reduced ejection fraction (HFrEF) and identify correlates of deteriorating renal function. Methods: A total of 381 patients with HFrEF enrolled in a prospective cohort study between 2006–2014 had eGFR measured at initial visit and at 1 year. Baseline characteristics were used in a multivariate analysis to establish variables that predict deterioration in eGFR. Follow-up data were used to assess whether declining eGFR was related to outcomes. Results: Patients were grouped into tertiles based on percentage change in eGFR. In a multivariate logistic regression analysis, male sex was associated with a 1.77-fold ([95% CI 1.01–2.89]; p = 0.045) and diabetes a 1.66-fold ([95% CI 1.02–2.70]; p = 0.041) greater risk of a decline in eGFR compared to those with stable/improving eGFR. Declining eGFR was associated with a 1.4-fold greater risk of death over 10 years ([95% CI 1.08–1.86]; p = 0.01) and a 3.12-fold ([1.44–6.75]; p = 0.004) greater risk of death at 1 year from second eGFR measurement. Conclusions: In patients with HFrEF diabetes and male sex are independent predictors of a decline in eGFR at 1 year. A decline eGFR over 1 year is associated with higher long-term all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Kearney et al. (2021) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=381). Declining eGFR vs. Stable/improving eGFR was evaluated on Death over 10 years (1.4-fold greater risk, 95% CI 1.08-1.86, p=0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: